{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:46:12Z","timestamp":1788839172584,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.urolonc.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T07:08:04Z","timestamp":1699945684000},"page":"461-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3108","authenticated-orcid":false,"given":"Jens","family":"Bedke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh Fran\u00e7ois","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Blake-Haskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossano","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Palou","family":"Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.10.004_bib0001","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0002","unstructured":"International Agency for Research on Cancer. Bladder cancer: World Health Organization. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30-Bladder-fact-sheet.pdf. Accessed 28 November 2022."},{"key":"10.1016\/j.urolonc.2023.10.004_bib0003","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non-muscle-invasive bladder cancer treated with bacillus calmette-guerin in the veterans affairs health system","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0006","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1007\/s00345-020-03569-2","article-title":"Follow-up in non-muscle invasive bladder cancer: facts and future","volume":"39","author":"Witjes","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0010","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0011","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0012","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000430501","article-title":"Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?","volume":"96","author":"Serretta","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-020-00642-1","article-title":"Can we treat bladder cancer with intravesical bacillus calmette-guerin in patients with prior tuberculosis infection? A population-based cohort study","volume":"20","author":"Hsu","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0014","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus calmette-guerin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1148\/rg.2019180014","article-title":"Complications of intravesical BCG immunotherapy for bladder cancer","volume":"39","author":"Green","year":"2019","journal-title":"Radiographics"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for non-muscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0017","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in non-muscle-invasive bladder carcinoma: a systematic review","volume":"38","author":"Mori","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0018","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 Urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0020","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cam4.3007","article-title":"Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis","volume":"9","author":"Jobczyk","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.urolonc.2023.10.004_bib0021","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/tau.2019.01.15","article-title":"Prediction tools in non-muscle invasive bladder cancer","volume":"8","author":"Zamboni","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0022","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0023","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","article-title":"Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models","volume":"8","author":"Guerrero-Ramos","year":"2022","journal-title":"Bladder Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2023.10.004_bib0024","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2021.11.002","article-title":"Somatic features of response and relapse in non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"5","author":"Bacon","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0025","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0026","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0028","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0029","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0030","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of non-muscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euf.2018.07.005","article-title":"Combination intravesical chemotherapy for non-muscle-invasive bladder cancer","volume":"4","author":"Steinberg","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"9","key":"10.1016\/j.urolonc.2023.10.004_bib0033","first-page":"e1-9 e7","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0034","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0036","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0037","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with Bacillus Calmette-Guerin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211039052","article-title":"Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma","volume":"13","author":"Yassaie","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0041","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0042","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0043","series-title":"Presented at the 21st Annual Meeting of the Society of Urologic Oncology, Inc.","article-title":"Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER TRIAL) [abstract]","author":"Hahn","year":"2020"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0044","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without Bacille Calmette-Guerin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0046","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.21873\/anticanres.13472","article-title":"To combine or not combine: drug interactions and tools for their analysis. Reflections from the EORTC-PAMM course on preclinical and early-phase clinical pharmacology","volume":"39","author":"El Hassouni","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0047","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0048","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","article-title":"Role of immunotherapy in bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer","volume":"36","author":"Mukherjee","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0049","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0050","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0051","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0052","first-page":"466","article-title":"Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease","volume":"15","author":"Yu","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0053","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2017.04.102","article-title":"Differential expression of PD-L1 in high grade T1 vs muscle invasive bladder carcinoma and its prognostic implications","volume":"198","author":"Wankowicz","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0054","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.21037\/tau-20-1436","article-title":"Narrative review: update on immunotherapy and pathological features in patients with bladder cancer","volume":"10","author":"Aurilio","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/2326-6066.CIR-22-0157","article-title":"BCG-induced tumor immunity requires tumor-intrinsic CIITA independent of MHC-II","volume":"10","author":"Redelman-Sidi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0056","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2326-6066.CIR-15-0176","article-title":"Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor","volume":"4","author":"Vandeveer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0057","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0058","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.2022.40.6_suppl.545","article-title":"PD-L1 expression and BCG response in non-muscle invasive bladder cancer [abstract]","volume":"40","author":"Woldu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0059","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0060","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 [abstract]","volume":"39","author":"Black","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0062","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 [abstract]","volume":"38","author":"Black","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0063","doi-asserted-by":"crossref","first-page":"TPS4589","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589","volume":"37","author":"Roupret","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0064","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-022-04415-5","article-title":"Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models","volume":"89","author":"DeAngelis","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0065","doi-asserted-by":"crossref","first-page":"TPS593","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS593","volume":"40","author":"Van Der Heijden","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0066","unstructured":"European Union Clinical Trials Registry. A phase 3, open-label, multi-center, randomized study evaluating the efficacy and safety of TAR-200 in combination with cetrelimab versus intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in participants with BCG-na\u00efve high-risk non-muscle invasive bladder cancer (HR-NMIBC). https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004506-64\/PL. Accessed March 13, 2023."},{"key":"10.1016\/j.urolonc.2023.10.004_bib0067","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","article-title":"A phase 2 study of durvalumab for Bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder","volume":"29","author":"Li","year":"2023","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.urolonc.2023.10.004_bib0068","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0069","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"S5","key":"10.1016\/j.urolonc.2023.10.004_bib0070","doi-asserted-by":"crossref","first-page":"S723","DOI":"10.1016\/j.annonc.2021.08.114","volume":"32","author":"Shariat","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0071","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Guerin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0072","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2019.0836","article-title":"Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial","volume":"5","author":"Johnson","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101589","article-title":"A phase Ib\/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma","volume":"8","author":"Cho","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0074","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cells11030357","article-title":"New perspectives in the medical treatment of non-muscle-invasive bladder cancer: immune checkpoint inhibitors and beyond","volume":"11","author":"Audisio","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0076","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"CORE1: phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guerin [abstract]","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0077","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol."},{"key":"10.1016\/j.urolonc.2023.10.004_bib0078","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0079","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"CMAJ"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1093194","article-title":"Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0081","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0082","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0083","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0084","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/cancers14102460","article-title":"Mechanism and management of checkpoint inhibitor-related toxicities in genitourinary cancers","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0086","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0087","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1138305","article-title":"Baseline risk factors associated with immune related adverse events and atezolizumab","volume":"13","author":"Madjar","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0088","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0089","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0090","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.3390\/ijms241310919","article-title":"Pembrolizumab-induced fatal myasthenia, myocarditis, and myositis in a patient with metastatic melanoma: autopsy, histological, and immunohistochemical findings-a case report and literature review","volume":"24","author":"Giovannini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2023.10.004_bib0091","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923003423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923003423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:39Z","timestamp":1761042519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923003423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1078143923003423"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.10.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}